Navigation Links
ViewRay Demonstrates Potential Therapy Applications for MRI-Guided Radiation at ASTRO 2011
Date:9/29/2011

CLEVELAND, Sept. 29, 2011 /PRNewswire/ -- ViewRay™, Inc., a privately held medical device company, will present potential applications for MRI-guided radiotherapy at the annual meeting of the American Society for Radiation Oncology (ASTRO) October 2 – 4 in Miami Beach, Florida, with software demonstrations in booth #865. The company's new research radiation therapy system is being developed to feature a patented combination of radiotherapy delivery and simultaneous magnetic resonance imaging (MRI). The system is being designed to let radiation oncologists see what they're treating, while they're treating.

Visitors to ViewRay's ASTRO booth can view software demonstrations and learn about the key capabilities being designed into the system. In addition to quality pretreatment imaging and advanced treatment delivery, the ViewRay system is being developed to enable:

  • On-table dose prediction — fast dose prediction using volumetric image data captured just prior to treatment.
  • Soft-tissue targeting — continuous, MRI-guided tracking of soft tissues and automatic beam control for real-time adaptation to motion.
  • Adaptive optimization — fast, convenient reoptimization for effective online and offline plan adaptation.
  • Review and assessment — software tools that help physicians better understand and manage the progress of treatment.

ViewRay holds the exclusive worldwide license for its combination of MRI and radiation therapy technologies. Earlier this year, landmark patents were issued for ViewRay's core technology in both the United States and Europe. ViewRay's treatment planning and delivery software recently received 510(k) premarket notification clearance from the U.S. FDA, and its integrated imaging and radiotherapy delivery system is now pending 510(k) review. The ViewRay system is currently available only as a non–human use research system.

"With the 510(k) clearance of our software, the issuance of patents on our technology, and the addition of several new research partners, we've reached major milestones this year," said ViewRay President and CEO Gregory M. Ayers, MD, PhD. "We're looking forward to sharing our progress with the ASTRO community." ViewRay research partners now include the University of California, Los Angeles (UCLA) Health System – Jonsson Comprehensive Cancer Center, the University of Wisconsin Carbone Cancer Center, and the Siteman Cancer Center at Barnes Jewish Hospital and Washington University School of Medicine, where the first ViewRay research system is currently being installed.

About ViewRay

ViewRay, Inc., of Cleveland, Ohio, is a privately held medical device company developing advanced radiation therapy technology for the treatment of cancer. The ViewRay system is being designed to provide continuous soft-tissue imaging during treatment, using MRI-guided radiotherapy, so that clinicians will be able to see where the actual radiation dose is being delivered and adapt to changes in the patient's anatomy. For more information, visit http://www.viewray.com.

ViewRay acknowledges the contribution of the State of Ohio, Department of Development and Third Frontier Commission, which provided funding in support of the MRI Technology Enabling Expansion of MRI into Radiotherapy Guidance Project.

ViewRay is a trademark of ViewRay, Inc.


'/>"/>
SOURCE ViewRay, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ViewRay Wins NorTech Innovation Award
2. Siteman Cancer Center at Barnes-Jewish and Washington University to Receive First ViewRay Radiation Therapy System
3. ViewRay Secures Series C Financing
4. ViewRay Receives FDA 510(k) Marketing Clearance for Treatment Planning and Delivery Software
5. University of Wisconsin Carbone Cancer Center to Acquire ViewRay Radiation Therapy System
6. Landmark Patents Issued for ViewRay Technology
7. UCLA Health System - Jonsson Comprehensive Cancer Center to Acquire ViewRay Radiation Therapy Research System
8. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
9. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
10. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
11. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
Breaking Medicine News(10 mins):